- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04385173
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background
- B7-H3 is expressed in 70% of patients with glioblastoma
- B7-H3 is not expressed in normal tissues especially not in central nervous system. Therefore, it is an attractive GBM target for CAR-T therapy
- The investigators constructed a retroviral vector encoding a chimeric antigen receptor (CAR) targeting B7-H3, which can mediate CAR transfer into patient T cells with high efficiency.
Objectives
- To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles
- To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles to the historical Temozolomide data
- To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles
Design
Patients autologous T cells are activated and transduced with retrovirus containing B7-H3 CAR. CAR-T cells are expanded ex vivo and infused back to patients via intratumoral or intracerebroventricular injection through an Ommaya catheter. 3 injections of CAR-T are planned at two different doses with 1-2 weeks intervals. The CAR-T injections occur in between Temozolomide (TMZ) cycles. Temozolomide treatment in the cycle of CAR-T injections will be stopped and resumed next cycle. Patients may receive additional CAR-T cycles at the discretion of the principal investigator and oncologist.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jianmin Zhang, MD
- Phone Number: +86-13805722695
- Email: 2307010@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- Jianmin Zhang, MD
- Phone Number: 86-13805722695
- Email: 2307010@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented informed consent of the participant and/or legally authorized representative.
- Histologically confirmed diagnosis of World Health Organization (WHO) classification grade IV glioblastoma (GBM).
- Clinical Pathology confirms B7-H3 positive tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score >= 50).
- Relapsed/refractory disease confirmed by radiographic evidence after standard therapy.
- Suitable for the surgery of the placement of the Ommaya catheter.
- Eastern Cooperative Oncology Group (ECOG) =0 or 1 (need to be confirmed before intratumoral or intracerebroventricular injection)
- >= 8 weeks after completion of front-line radiation therapy
- >= 6 weeks after completion of nitrourea chemotherapy
- >= 14 days after completion of Temozolomide or other chemotherapy
- 2 weeks of wash-out time after completion of targeted therapy with related adverse events (AE) on baseline (4 weeks for Bevacizumab).
- Patients with other chronic AEs are in the investigator's judgement
- Blood cell count: White blood count (WBC) >= 2000/μL;Neutrophil count >= 1500/μL;Platelets >= 100 x 103/μL;Hemoglobin >= 9.0 g/dL
- Serum Creatinine <= 1.5×ULN or Creatinine Clearance Rate (Cockcroft and Gault) > 30 mL/min/1.73 m2
- Alanine Transaminase (ALT) <= 5×ULN and total bilirubin < 2.0mg/dL
- Lung function: Oxygen (O2) saturation >= 92% on room air and < CTCAE grade 1 dyspnea
- Heart function: Left ventricular ejection fraction (LVEF) >= 40% by multigated acquisition (MUGA) scan or echocardiogram
- Normal coagulation function: prothrombin time (PT),activated partial thromboplastin time (APTT) and international normalized ratio (INR)
- Good blood vessel condition for leukapheresis
- Women of childbearing potential (WOCBP): negative urine or serum pregnancy test
- Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity within one year after B7-H3 CAR-T infusion
Exclusion Criteria:
- Other active malignancy in the past 2 years except non-melanoma skin cancer, completely surgical removed low grade tumor, posttherapeutic limited-stage prostate cancer, biopsy confirmed in situ cervical carcinoma, PAP test confirmed squamous intraepithelial lesions
- Participant is undergoing or planning to take other anti-tumor therapies
- Participant is systematic steroid-dependent, or is expecting to be treated with systematic steroid
- Active immunodeficiency virus (HIV) or hepatitis B or hepatitis C virus infection
- Active infection from fungi, bacteria and/or viruses
- Known history of the following cardiac diseases in the past 6 months:
- New York Heart Association (NYHA) defined grade III or IV heart failure, cardiac angioplasty, myocardial infarction, unstable angina and other clinically significant heart diseases
- Known history and/or clinically evident central nerve system diseases: seizure, epileptic seizure, aphasia, paralysis, stroke, severe brain damage, dementia, Parkinson's Disease, cerebellar diseases, organic brain syndrome and psychiatric disorders
- Autoimmune diseases
- Pregnant or breastfeeding females
- Therapeutic doses of corticosteroid within 7 days before leukapheresis or 72 hours before B7-H3 CAR-T infusion
- Cytotoxic chemotherapy without lymphocytotoxicity within 1 week before leukapheresis except that the treatment has been stopped for more than 3 half-lives of the drug
- Lymphocytotoxic chemotherapy (cyclophosphamide, Ifosfamide and bendamustine) within 2 weeks before leukapheresis
- Other clinical trials drugs within 4 weeks before leukapheresis except that the drug has no effect or the disease has progressed, and the treatment has been stopped for more than 3 half-lives of the drug
- Radiotherapy within 6 weeks before leukapheresis
- Prior trials of CAR-T or other cell therapy
- Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: B7-H3 CAR-T
Patients will received regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval.
3 infusions of B7-H3 CAR-T with 1-2 weeks of interval will be used in between cycles of Temozolomide treatment.
Temozolomide treatment during B7-H3 CAR-T infusions will be stopped and resumed after CAR-T infusion.
|
The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles.
Temozolomide will be stopped during the infusion of B7-H3 CAR-T
Other Names:
Temozolomide will be given to patients orally every 5 days with 23 days interval.
The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen.
If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and type of adverse events
Time Frame: 12 weeks
|
Number of Participants With Treatment-Related Adverse Events and Types of adverse events as Assessed by CTCAE v4.0
|
12 weeks
|
Maximum tolerated dose (MTD)
Time Frame: 12 weeks
|
The highest dose of B7-H3 CAR-T that does not cause targeted dose limiting toxicity
|
12 weeks
|
Overall survival (OS)
Time Frame: 2 years, up to 15 years if necessary
|
Kaplan Meier methods will be used to estimate median OS
|
2 years, up to 15 years if necessary
|
Progression-free survival (PFS)
Time Frame: 2 years, up to 15 years if necessary
|
Kaplan Meier methods will be used to estimate median PFS.
Progression is defined by Response Assessment in Neuro-Oncology (RANO) criteria
|
2 years, up to 15 years if necessary
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The pharmacokinetics (PK) of B7-H3 CAR-T
Time Frame: 12 weeks
|
Peak Concentration (Cmax) of B7-H3 CAR-T in peripheral blood (PB) and cerebral spinal fluid (CSF)
|
12 weeks
|
The pharmacokinetics (PK) of B7-H3 CAR-T
Time Frame: 12 weeks
|
Area under the concentration versus time curve (AUC) of B7-H3 CAR-T in peripheral blood (PB) and cerebral spinal fluid (CSF)
|
12 weeks
|
Disease response (ORR, CR, PR, DOR)
Time Frame: 2 years, up to 15 years if necessary
|
Objective Response Rate (ORR) will be assessed by comparison with baseline magnetic resonance imaging by RANO.
Complete Response (CR) is disappearance of all measurable and non-measurable disease for at least 4 weeks.
Partial Response (PR) is >/= 50% decrease in lesions for at least 4 weeks.
Duration of Response (DOR) is the time between the initial response to the treatment and subsequent disease progression.
|
2 years, up to 15 years if necessary
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cytokine levels in PB and CSF
Time Frame: 12 weeks
|
The concentration of cytokines (IL-1, IL-2, IL-6, IL-10, TNF-α, IFN-γ) in PB and CSF
|
12 weeks
|
T cell phenotype
Time Frame: 12 weeks
|
The chimeric antigen receptor positive (CAR+) T cell and memory/effector T cell percentages and cell counts detected in peripheral blood (PB), and cerebral spinal fluid (CSF).
Statistical and graphical methods will be used to describe persistence and expansion
|
12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Recurrence
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
Other Study ID Numbers
- SAHZJU-BP102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
Clinical Trials on B7-H3 CAR-T
-
St. Jude Children's Research HospitalRecruitingGlioblastoma | Central Nervous System Neoplasms | High Grade Glioma | Ependymoma | Medulloblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | Atypical Teratoid/Rhabdoid TumorUnited States
-
Beijing Tiantan HospitalRecruiting
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.RecruitingRelapsed/Refractory Acute Myeloid LeukemiaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Tianjin Medical University Cancer Institute and Hospital; Shandong Cancer Hospital...RecruitingB7-H3-positive Relapsed/ Refractory NeuroblastomaChina
-
Crystal Mackall, MDRecruitingBrain and Nervous SystemUnited States
-
Second Affiliated Hospital of Guangzhou Medical...Guangdong Zhaotai InVivo Biomedicine Co. Ltd.; Hunan Zhaotai Yongren Medical...RecruitingCancer | Lung Cancer | Immunotherapy | CAR-T CellChina
-
Second Affiliated Hospital of Soochow UniversitySoochow T-Maximun Biotechnology Co. LTDRecruitingAdvanced Glioma | Complication of Chimeric Antigen Receptor (CAR-T) Cell TherapyChina
-
Second Affiliated Hospital, School of Medicine,...Huizhou Municipal Central Hospital; BoYuan RunSheng Pharma (Hangzhou) Co.,... and other collaboratorsRecruitingRecurrent Glioblastoma | Refractory GlioblastomaChina
-
St. Jude Children's Research HospitalRecruitingMelanoma | Soft Tissue Sarcoma | Carcinoma | Osteosarcoma | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Desmoplastic Small Round Cell Tumor | Pediatric Solid Tumor | Clear Cell Sarcoma | Malignant Peripheral Nerve Sheath Tumors | Adrenocortical Cancer | Germ Cell CancerUnited States
-
Second Affiliated Hospital of Guangzhou Medical...Guangdong Zhaotai InVivo Biomedicine Co. Ltd.RecruitingBreast Cancer | Lung Cancer | Brain Tumor | Colo-rectal Cancer | Liver Cancer | Solid Tumor, Adult | CTLA4 | PD1China